Furthermore, genes that encode enzymes capable of conferring to tumor cells sensitivity to chemotherapeutic agents may be introduced. Intracellular and internal proteins. In one embodiment the invention relates to a vaccine composition comprising one or more pharmamers and one or more biologically active molecules, wherein the one or more biologically active molecules are attached to some but not all of the one or more pharmamers. The Mamu class 1 molecules are folded or partly folded with human b2Microglobulin and a peptide fitting into the binding groove. In contrast to traditional vaccines against infectious diseases, cancer vaccines are designed to be injected after the disease is diagnosed, rather than before it develops and are therefore therapeutic. Immunologically active molecules of special interest for the present invention can be selected from the groups listed below:
|Date Added:||26 March 2015|
|File Size:||32.13 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
In the method of the present invention, the therapeutic nucleic acid sequence is a nucleic acid coding for a product, wherein the product causes cell death by itself or in the presence of other drugs. Aluminum hydroxide has also been described as activating the complement pathway. A pharmamer can comprise several immunologically active molecules which can be the same or different.
Furthermore, it is also possible to specifically modulate the activity of more than one MHC recognising cell clone by choosing the before-mentioned other molecules appropriately. Thus, the present invention provides MHC complexes which present mono-valent or multi-valent binding sites for MHC recognising cells, such as MHC complexes tkii comprising a multimerization domain, such as a scaffold or a carrier molecule, which multimerization domain have attached thereto, directly or indirectly via one or more linkers, covalently 2401b non-covalently, one or more MHC peptide complexes.
FIELD OF INVENTION
NHS-esters react with amines to form amide bonds. Furthermore the immunotherapeutic agent may be any cytokine or interferon. Example, prophylactic vaccines are conventional vaccines for infectious diseases, such as measles, mumps, and tetanus. When selecting biologically active molecules to be used in a pharmamer one needs to carefully 24410b the possibilities of unwanted adverse or serious adverse reactions.
Related diseases include intestinal inflammations, such as Coeliac disease, proctitis, eosinophilia gastroenteritis, mastocytosis, inflammatory bowel disease, Chrohn’s disease and ulcerative colitis, as well as food-related allergies.
The immunotherapeutic agent can be e. For example, a single dose can be given once, or a dose can be given as a primer, followed by one or more administration, or a continuous administration regime like up to four doses per week, followed by one month without administrations, followed by up to four doses per week.
Acer Aspire 3000, 5000, Hp Compaq nx7000, nx7010 Notebook Dc Power Jack
Adjuvants with bacterial origins can be purified and synthesized e. In the following principles for attachment of biologically active molecules to multimerisation domains are described, but same principles may be applied to attachment of adjuvant molecules, immune target molecules or any other molecules to multimerisation domains.
Certain compounds will be more potent than others. The silicone elastomer can also comprise albumin. Vaccines are either toi and prevent disease or therapeutic and treat disease. Optionally the gene encoding the intracellular or internal protein or a fragment of the protein may be fused to a gene encoding a protein tag for e.
HSP70 induces a robust mucosal immune response. Surface proteins, including full length protein, truncated or otherwise modified proteins.
The term liposome as used herein is defined as a spherical vesicle with a membrane composed of a phospholipid and cholesterol bilayer. Preferably, the vaccine compositions are administered in the range of 2 to 10 times, more preferably in the range of 2 to 5 times, such as twice.
Furthermore, the invention encompasses a therapeutic composition further comprising any adjuvant substance including any of the above or combinations thereof. However, in other embodiments of the invention the pharmaceutical composition may comprise no buffer at all or only micromolar amounts of buffer. Although tumour cells can prime the immune system, tumour escape mechanisms can induce immunological tolerance to the tumour.
The support configuration can be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Compositions of pharmamers may be used for prophylactic vaccination of individuals to protect the individual against e.
As used herein the term vaccine is used for an antigenic preparation used to establish partial or total immunity to a disease or illness and thereby protecting, curing or treating the body from a specific disease or illness. When the MHC complex comprises a multimerization domain to which the n MHC-peptide complexes tii associated, the association can be a covalent linkage so that each or at least some of the n MHC-peptide complexes is covalently linked to the multimerization domain, or the association can be a non-covalent association so that each or at least some of the n MHC-peptide complexes are non-covalently associated with the multimerization domain.
The nature of the one or more multimerization domain s can be either soluble to some extent or insoluble for the purposes of the present invention. The therapeutic compositions of 241b invention can suitably be applied in the treatment, prevention, stabilisation, or alleviation of various diseases. The present invention relates in one embodiment to a vaccine composition comprising one or more pharmamers, wherein the one or more pharmamers comprises more than 1 identical multimerization domain such as more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, tmi, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,,,1, 2, 3, 4, 5, 6, 7, 8, 9, or more than 10, identical multimerization domains.
The present invention relates in one embodiment to a vaccine composition comprising one or more pharmamers, wherein one or more pharmamers comprises less than 10, identical multimerization domains, such as for example less than 9, 8, 7, 6, 5, 4, 3, 2, 1,,,95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, or less than 2 identical multimerization domains.
Notebook Laptop Power Jack Modelleri –
The MHC complexes have a large variety of applications that include targeting of high affinity receptors e. In a further embodiment the present invention relates to a vaccine composition comprising less than 10, identical pharmamers, such as for example less than 9, 8, 7, 6, 5, 4, 3, 2, 1,,,95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, or less than 2 identical pharmamers.
A suitable administration form for parenteral administration is a solution or dispersion. Also included herein is the various responses belonging to the innate immune response.